What is bovine mesenteric fat and why is it used in supplements?

Bovine mesenteric fat is the visceral adipose tissue surrounding the intestines of cattle. It is of research interest because it contains proteins such as GC-C and GNY that showed anti-lipogenic activity in bovine adipocyte cell culture studies, though no supplement manufacturer has yet established a clinically validated use case for human consumption.

Does bovine mesenteric fat have any proven health benefits for humans?

No human health benefits have been established for bovine mesenteric fat. All research to date has been conducted in animal models or cell cultures, and the one notable liver regeneration study used stem cells from rat mesenteric fat, not bovine-derived material, in a cirrhotic rat model of only 30 animals.

What are the GC-C and GNY proteins found in bovine mesenteric fat?

GC-C and GNY are bioactive proteins identified within bovine mesenteric adipose tissue that demonstrated the ability to inhibit fat accumulation in bovine adipocytes in vitro. Their precise molecular targets, such as specific lipogenic enzymes or transcription factors like SREBP-1c or PPAR-gamma, have not been fully characterized, and their activity in human cells remains untested.

Is bovine mesenteric fat safe to take as a supplement?

There are no published human safety or toxicology studies for bovine mesenteric fat as an oral supplement, so a safety profile cannot be established. People with allergies to beef or bovine-derived products face clear contraindication risk, and the absence of pharmacokinetic data means appropriate dosing, metabolism, and elimination are all unknown.

How does bovine mesenteric fat differ from other animal fat supplements like beef tallow?

Unlike beef tallow, which is a rendered subcutaneous or mixed fat used primarily as a dietary fat source rich in saturated fatty acids and fat-soluble vitamins, bovine mesenteric fat is a specific visceral adipose depot studied for its protein content rather than its fatty acid profile. The research interest in mesenteric fat centers on bioactive proteins like GC-C and GNY rather than caloric or lipid composition, representing a fundamentally different proposed mechanism than conventional animal fat supplements.

What does current research show about bovine mesenteric fat's effectiveness in humans?

Current clinical evidence for bovine mesenteric fat in humans is extremely limited, with no published human trials demonstrating health benefits. Available research is restricted to animal models, primarily involving rat-derived mesenteric stem cells in liver disease studies, which cannot be directly extrapolated to human safety or efficacy. The proteins GC-C and GNY have only been studied in isolated bovine fat cells in laboratory conditions, not in living human subjects. Any health claims about bovine mesenteric fat should be considered preliminary and unproven until rigorous human clinical trials are completed.

Are there any known drug interactions or contraindications with bovine mesenteric fat supplements?

Due to the complete lack of human clinical trials and minimal research on bovine mesenteric fat, specific drug interactions have not been established or studied. Individuals taking anticoagulants, anti-inflammatory medications, or supplements that affect fat metabolism should consult a healthcare provider before use, as animal-derived fat supplements may theoretically influence these therapies. The absence of documented interactions does not confirm safety, but rather reflects the ingredient's minimal human research base. Anyone on prescription medications should seek medical guidance before adding this supplement to their regimen.

Who should avoid bovine mesenteric fat supplements, and are there any population-specific concerns?

Bovine mesenteric fat supplements should be avoided by pregnant women, nursing mothers, and children due to the complete absence of safety data in these vulnerable populations. Individuals with documented beef allergies or sensitivities to animal-derived products should not use this ingredient, and those with liver disease should exercise caution despite preliminary rat studies suggesting potential benefits. People following vegan or vegetarian diets would naturally avoid this animal-derived supplement. Given the lack of human safety evidence, older adults or those with multiple comorbidities should obtain medical clearance before use.

Bovine Mesenteric Fat

Bovine mesenteric fat is visceral adipose tissue harvested from cattle that contains bioactive proteins, including GC-C and GNY, which have been shown to inhibit fat accumulation in bovine adipocytes in vitro. Research remains confined to animal and cell-culture models, with no established human health benefits or clinically validated applications as of current literature.

Category: Other Evidence: 2/10 Tier: Emerging

Bovine Mesenteric Fat — Hermetica Encyclopedia

Origin & History

Bovine mesenteric fat is the visceral adipose tissue surrounding the intestines (mesentery) sourced from cattle (Bos taurus), typically obtained as a byproduct of slaughter. It contains adipocytes rich in triglycerides and proteins like guanylyl cyclase C (GC-C) and guanylin (GNY), though no standardized commercial supplement extraction method exists.

Historical & Cultural Context

No evidence of bovine mesenteric fat use in traditional medicine systems was found. All research focuses on modern biomedical contexts like stem cell derivation or lipid regulation studies, without any historical or cultural references.

Health Benefits

• No human health benefits established - all research limited to animal models
• Stem cells derived from mesenteric fat (rat, not bovine) improved liver regeneration in cirrhotic rats (n=30) - preliminary evidence only
• Contains GC-C and GNY proteins that inhibit fat accumulation in bovine adipocytes in vitro - no human relevance established
• Surgical removal of mesenteric fat in baboons (n=4) showed metabolic benefits - not applicable to oral supplementation
• No clinical evidence supporting any health benefits in humans

How It Works

Bovine mesenteric fat contains GC-C and GNY proteins that act within adipocytes to suppress lipid droplet accumulation, likely by modulating lipogenic enzyme activity or fatty acid uptake pathways, though the precise receptor targets in bovine cells have not been fully characterized. Separately, stem cells isolated from rodent mesenteric fat (not bovine) have demonstrated hepatoprotective effects in cirrhotic rat models, potentially through paracrine signaling that promotes hepatocyte regeneration and reduces fibrotic remodeling. No mechanistic data from human cell lines or human tissue currently exists for bovine mesenteric fat specifically.

Scientific Research

No human clinical trials, RCTs, or meta-analyses exist for bovine mesenteric fat as a supplement. Research is limited to preclinical animal models, including rat studies on derived stem cells and baboon surgical removal studies, with no PubMed PMIDs identified for human supplementation studies.

Clinical Summary

All available research on mesenteric fat-derived bioactives is limited to animal models and in vitro cell studies, with zero completed human clinical trials identified in the literature. A preliminary animal study using stem cells derived from rat mesenteric fat in cirrhotic rats (n=30) reported improved liver regeneration markers, but this used rodent-derived cells, not bovine tissue, making direct extrapolation to bovine mesenteric fat supplementation scientifically unsupported. The GC-C and GNY protein findings originate from bovine adipocyte cell culture experiments and have not been replicated in vivo or in humans. Evidence strength is currently rated as insufficient to make any health claims for human supplementation.

Nutritional Profile

Bovine mesenteric fat is a visceral adipose tissue with a composition dominated by lipids (approximately 85-92% total fat by wet weight), with minor contributions from protein (~2-4%) and water (~5-10%). The fatty acid profile is characteristic of ruminant visceral fat: saturated fatty acids predominate at approximately 45-55% of total fatty acids, with palmitic acid (C16:0) at ~25-30% and stearic acid (C18:0) at ~15-20%. Monounsaturated fatty acids account for ~35-45%, primarily oleic acid (C18:1n-9). Polyunsaturated fatty acids are low at ~3-5%, with linoleic acid (C18:2n-6) at ~2-3% and alpha-linolenic acid (C18:3n-3) at <1%. Contains conjugated linoleic acid (CLA, primarily c9,t11 isomer) at approximately 0.3-0.6% of total fatty acids, a level comparable to other bovine adipose depots. Cholesterol content is approximately 70-90 mg per 100g of tissue. Fat-soluble vitamins are present in modest amounts: vitamin E (tocopherols) at approximately 0.3-0.6 mg/100g; vitamin K2 (menaquinones, particularly MK-4) estimated at 5-15 mcg/100g based on comparable ruminant fat data. Bioactive compounds include GC-C (granulocyte colony-stimulating factor-related) and GNY proteins identified in bovine mesenteric adipocytes in vitro, though concentrations in consumed tissue and oral bioavailability in humans are not established. Mineral content is minimal given the high lipid fraction: trace amounts of iron, zinc, and selenium expected at <0.5 mg/100g combined. As a rendered or raw fat source, fiber content is zero. Bioavailability of saturated and monounsaturated fatty acids from ruminant fat is generally high (>90% intestinal absorption), though mesenteric-depot-specific absorption data in humans is absent. The high stearic acid content is notable as stearic acid is considered relatively neutral with respect to LDL cholesterol compared to other saturated fatty acids.

Preparation & Dosage

No clinically studied dosage ranges exist for bovine mesenteric fat in humans, as it has never been tested as a human supplement. No standardized forms or preparations are available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

None established - no synergistic ingredients identified in research

Safety & Interactions

No formal human safety profile, toxicology studies, or pharmacokinetic data exist for bovine mesenteric fat as an oral supplement, making it impossible to define a safe or effective dose. Individuals with beef or bovine-derived product allergies should avoid this ingredient due to obvious cross-reactivity risk. Potential interactions with lipid-lowering medications such as statins or fibrates cannot be ruled out given the fat-derived and lipid-modulating nature of the material, though no interaction studies have been conducted. Pregnant or breastfeeding individuals should avoid use entirely due to a complete absence of safety data in these populations.